

Claims

- 6 -

### CLAIMS

1. L-(-)-moprolol L-(+)-tartrate salt (2:1).
2. Pharmaceutical composition for ophthalmic use, characterized in that it comprises L-(-)-moprolol L-(+)-tartrate (2:1) together with at  
5 least one pharmaceutically acceptable vehicle.
3. Pharmaceutical composition according to Claim 2, characterized in that it is in the form of a gel, an ointment or eyedrops.
4. Pharmaceutical composition according to Claim 2 or 3, characterized in that the amount of L-(-)-moprolol is between  
10 0.01% and 20% by weight.
5. Pharmaceutical composition according to Claim 2 or 3, characterized in that the amount of L-(-)-moprolol is between 1% and 8% by weight.
6. Process for preparing L-(-)-moprolol L-(+)-tartrate (2:1),  
15 characterized in that it includes the addition of L-(+)-tartaric acid, dissolved in a suitable organic solvent, to L-(-)-moprolol base, also dissolved in a suitable organic solvent, in a 2:1 molar ratio.
7. Process according to Claim 6, characterized in that the salt thus formed is isolated via precipitation and filtration.
- 20 8. Process according to Claim 6 or 7, characterized in that the abovementioned organic solvent is ethyl alcohol.
9. Process according to Claim 8, characterized in that the salt is precipitated from the ethanolic solution via addition of ethyl ether.